Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Elevated desmoglein-2 is a prognostic marker across genomic subtypes w/ impact on high-risk cytogenetics & distinct GEP associated w/ downregulation of pathways related to ribosomes, nonsense-mediated decay and translation.”
Title: Elevated desmoglein-2 expression in multiple myeloma is a prognostic marker across genomic subtypes with impact on high-risk cytogenetics and a distinct gene expression profile
Authors: Barbara J. McClure, John Toubia, Charlotte E. J. Toomes, O. Giles Best, Angelina Yong, Cindy H. Lee, Claudine S. Bonder, Chung Hoow Kok
You can read the Full Article in British Journal of Haematology.
You can find other articles featuring Robert Orlowski on OncoDaily.
